Literature DB >> 8891149

Microdilution antifungal susceptibility testing of Candida albicans and Cryptococcus neoformans with and without agitation: an eight-center collaborative study.

E J Anaissie1, V L Paetznick, L G Ensign, A Espinel-Ingroff, J N Galgiani, C A Hitchcock, M LaRocco, T Patterson, M A Pfaller, J H Rex, M G Rinaldi.   

Abstract

The growth patterns observed in the trailing wells when fluconazole is being tested may give rise to readings that suggest resistance or increased MICs for known susceptible strains. We conducted a multicenter study to evaluate the intralaboratory and interlaboratory reproducibilities of a method that uses agitation to disperse these types of growth. Ten strains of Candida albicans and five strains of Cryptococcus neoformans were tested against fluconazole, flucytosine, and amphotericin B by using a microdilution adaptation of the proposed reference method of the National Committee for Clinical Laboratory Standards for yeasts (M27-T). The endpoint criterion used before agitation was consistent with the M27-T recommendation, while a criterion of 50% or more reduction of growth compared with the control was used after agitation. The results of this study showed that use of agitation and the modified endpoint criterion both improved intralaboratory and inter-laboratory agreement and increased the frequency of interpretable MICs. The MICs obtained by this method were comparable to those obtained by the broth macrodilution M27-T method. Like M27-T, this method was not able to definitely distinguish amphotericin B-susceptible from -resistant strains, although the MICs for the resistant strains were consistently higher than those for the susceptible ones. The findings imply that agitation should be seriously considered when antifungal agents, particularly fluconazole, are tested in a microdilution format.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8891149      PMCID: PMC163539     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

1.  Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests.

Authors:  A Espinel-Ingroff; C W Kish; T M Kerkering; R A Fromtling; K Bartizal; J N Galgiani; K Villareal; M A Pfaller; T Gerarden; M G Rinaldi
Journal:  J Clin Microbiol       Date:  1992-12       Impact factor: 5.948

2.  Standardized susceptibility testing of fluconazole: an international collaborative study.

Authors:  M A Pfaller; B Dupont; G S Kobayashi; J Müller; M G Rinaldi; A Espinel-Ingroff; S Shadomy; P F Troke; T J Walsh; D W Warnock
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

3.  Detection of amphotericin B-resistant Candida isolates in a broth-based system.

Authors:  J H Rex; C R Cooper; W G Merz; J N Galgiani; E J Anaissie
Journal:  Antimicrob Agents Chemother       Date:  1995-04       Impact factor: 5.191

4.  Multicenter evaluation of four methods of yeast inoculum preparation.

Authors:  M A Pfaller; L Burmeister; M S Bartlett; M G Rinaldi
Journal:  J Clin Microbiol       Date:  1988-08       Impact factor: 5.948

5.  Susceptibilities of serial Cryptococcus neoformans isolates from patients with recurrent cryptococcal meningitis to amphotericin B and fluconazole.

Authors:  A Casadevall; E D Spitzer; D Webb; M G Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

6.  Collaborative investigation of variables in susceptibility testing of yeasts.

Authors:  M A Pfaller; M G Rinaldi; J N Galgiani; M S Bartlett; B A Body; A Espinel-Ingroff; R A Fromtling; G S Hall; C E Hughes; F C Odds
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

7.  Multicenter evaluation of a broth macrodilution antifungal susceptibility test for yeasts.

Authors:  R A Fromtling; J N Galgiani; M A Pfaller; A Espinel-Ingroff; K F Bartizal; M S Bartlett; B A Body; C Frey; G Hall; G D Roberts
Journal:  Antimicrob Agents Chemother       Date:  1993-01       Impact factor: 5.191

8.  Results of a survey of antifungal susceptibility tests in the United States and interlaboratory comparison of broth dilution testing of flucytosine and amphotericin B.

Authors:  D L Calhoun; G D Roberts; J N Galgiani; J E Bennett; D S Feingold; J Jorgensen; G S Kobayashi; S Shadomy
Journal:  J Clin Microbiol       Date:  1986-02       Impact factor: 5.948

9.  Susceptibility testing of Cryptococcus neoformans: a microdilution technique.

Authors:  M A Ghannoum; A S Ibrahim; Y Fu; M C Shafiq; J E Edwards; R S Criddle
Journal:  J Clin Microbiol       Date:  1992-11       Impact factor: 5.948

10.  Fluconazole susceptibility testing of Candida albicans: microtiter method that is independent of inoculum size, temperature, and time of reading.

Authors:  E Anaissie; V Paetznick; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1991-08       Impact factor: 5.191

View more
  11 in total

1.  Comparison of three methods of determining MICs for filamentous fungi using different end point criteria and incubation periods.

Authors:  C Llop; I Pujol; C Aguilar; J Sala; D Riba; J Guarro
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

Review 2.  Antifungal susceptibility testing: practical aspects and current challenges.

Authors:  J H Rex; M A Pfaller; T J Walsh; V Chaturvedi; A Espinel-Ingroff; M A Ghannoum; L L Gosey; F C Odds; M G Rinaldi; D J Sheehan; D W Warnock
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

3.  Optimizing voriconazole susceptibility testing of Candida: effects of incubation time, endpoint rule, species of Candida, and level of fluconazole susceptibility.

Authors:  M Lozano-Chiu; S Arikan; V L Paetznick; E J Anaissie; J H Rex
Journal:  J Clin Microbiol       Date:  1999-09       Impact factor: 5.948

4.  Detection of resistance to amphotericin B among Cryptococcus neoformans clinical isolates: performances of three different media assessed by using E-test and National Committee for Clinical Laboratory Standards M27-A methodologies.

Authors:  M Lozano-Chiu; V L Paetznick; M A Ghannoum; J H Rex
Journal:  J Clin Microbiol       Date:  1998-10       Impact factor: 5.948

5.  Interpretation of trailing endpoints in antifungal susceptibility testing by the National Committee for Clinical Laboratory Standards method.

Authors:  S G Revankar; W R Kirkpatrick; R K McAtee; A W Fothergill; S W Redding; M G Rinaldi; T F Patterson
Journal:  J Clin Microbiol       Date:  1998-01       Impact factor: 5.948

6.  In vitro activity of nystatin compared with those of liposomal nystatin, amphotericin B, and fluconazole against clinical Candida isolates.

Authors:  Sevtap Arikan; Luis Ostrosky-Zeichner; Mario Lozano-Chiu; Victor Paetznick; David Gordon; Tom Wallace; John H Rex
Journal:  J Clin Microbiol       Date:  2002-04       Impact factor: 5.948

7.  Comparative evaluation of a new fluorescent carboxyfluorescein diacetate-modified microdilution method for antifungal susceptibility testing of Candida albicans isolates.

Authors:  Robert S Liao; Robert P Rennie; James A Talbot
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

Review 8.  Current and emerging azole antifungal agents.

Authors:  D J Sheehan; C A Hitchcock; C M Sibley
Journal:  Clin Microbiol Rev       Date:  1999-01       Impact factor: 26.132

Review 9.  Amphotericin-B colloidal dispersion. A review of its use against systemic fungal infections and visceral leishmaniasis.

Authors:  R N Brogden; K L Goa; A J Coukell
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546

10.  In vitro cytotoxicity of two novel oral formulations of Amphotericin B (iCo-009 and iCo-010) against Candida albicans, human monocytic and kidney cell lines.

Authors:  Carlos G Leon; Jinkyung Lee; Karen Bartlett; Pavel Gershkovich; Ellen K Wasan; Jinying Zhao; John G Clement; Kishor M Wasan
Journal:  Lipids Health Dis       Date:  2011-08-20       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.